In last trading session, Humacyte Inc (NASDAQ:HUMA) saw 1.94 million shares changing hands with its beta currently measuring 1.38. Company’s recent per share price level of $2.99 trading at -$0.01 or -0.33% at ring of the bell on the day assigns it a market valuation of $384.72M. That closing price of HUMA’s stock is at a discount of -233.44% from its 52-week high price of $9.97 and is indicating a premium of 6.02% from its 52-week low price of $2.81. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.3 million shares which gives us an average trading volume of 4.15 million if we extend that period to 3-months.
For Humacyte Inc (HUMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.25 in the current quarter.
Humacyte Inc (NASDAQ:HUMA) trade information
Upright in the red during last session for losing -0.33%, in the last five days HUMA remained trading in the red while hitting it’s week-highest on Thursday, 03/06/25 when the stock touched $2.99 price level, adding 9.12% to its value on the day. Humacyte Inc’s shares saw a change of -40.79% in year-to-date performance and have moved -5.08% in past 5-day. Humacyte Inc (NASDAQ:HUMA) showed a performance of -27.60% in past 30-days. Number of shares sold short was 25.48 million shares which calculate 13.45 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 62.62% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -100.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -100.67% for stock’s current value.
And 4 analysts are in estimates of company making revenue of 800.25k in the next quarter.
In 2025, company’s earnings growth rate is likely to be around -21.76% while estimates for its earnings growth in next 5 years are of 40.27%.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Insiders are in possession of 26.87% of company’s total shares while institution are holding 35.02 percent of that, with stock having share float percentage of 47.89%. Investors also watch the number of corporate investors in a company very closely, which is 35.02% institutions for Humacyte Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at HUMA for having 7.14 million shares of worth $34.27 million. And as of 2024-06-30, it was holding 6.5961 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 4.73 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.3693 of outstanding shares, having a total worth of $22.7 million.
